Modeling Chronic Coccidioidomycosis in Mice.
Coccidioides
Cp1038
Histopathology
Immunology
Intranasal
Mice
Quiescent
Survival
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
8
5
2023
pubmed:
5
5
2023
entrez:
5
5
2023
Statut:
ppublish
Résumé
Coccidioidomycosis, caused by the dimorphic pathogens Coccidioides posadasii and C. immitis, is a fungal disease endemic to the southwestern United States, Mexico, and some regions of Central and South America. The mouse is the primary model for studying pathology and immunology of disease. Mice in general are extremely susceptible to Coccidioides spp., which creates challenges in studying the adaptive immune responses that are required for host control of coccidioidomycosis. Here, we describe how to infect mice to model asymptomatic infection with controlled, chronic granulomas and a slowly progressive but ultimately fatal infection that has kinetics more similar to the human disease.
Identifiants
pubmed: 37145282
doi: 10.1007/978-1-0716-3199-7_11
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
139-158Informations de copyright
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Drutz DJ, Catanzaro A (1978) Coccidioidomycosis. Am Rev Resp Dis 117(559–585):727–771
pubmed: 347998
Galgiani JN, Blair JE, Ampel NM et al (2019) Treatment for early, uncomplicated coccidioidomycosis: what is success? Clin Infect Dis 70:2008–2012. https://doi.org/10.1093/cid/ciz933
doi: 10.1093/cid/ciz933
Cox RA, Magee DM (2004) Coccidioidomycosis: Host response and vaccine development. Clin Microbiol Rev 17:804–839
doi: 10.1128/CMR.17.4.804-839.2004
pubmed: 15489350
pmcid: 523560
Shubitz LF, Peng T, Perrill R et al (2002) Protection of mice against Coccidioides immitis intranasal infection by vaccination with recombinant antigen 2/PRA. Infect Immun 70:3287–3289. https://doi.org/10.1128/iai.70.6.3287-3289.2002
doi: 10.1128/iai.70.6.3287-3289.2002
pubmed: 12011027
pmcid: 127985
Shubitz LF, Perrill R, Lewis ML, et al (2011) Early post-infection detection of Coccidioides in intranasally infected mice. Proceedings 55th annual Coccidioidomycosis study group. University of California, Davis:40
Roberts LM, Tuladhar S, Steele SP et al (2014) Identification of early interactions between Francisella and the host. Infect Immun 82:2504–2510. https://doi.org/10.1128/IAI.01654-13
doi: 10.1128/IAI.01654-13
pubmed: 24686053
pmcid: 4019147
Galgiani JN, Ampel NM, Blair JE et al (2016) Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis 63:e112–e146. https://doi.org/10.1093/cid/ciw360
doi: 10.1093/cid/ciw360
pubmed: 27470238
Brewer JH, Parrott CL, Rimland D (1982) Disseminated coccidioidomycosis in a heart transplant recipient. Sabouraudia 20:261–265. https://doi.org/10.1080/00362178285380381
doi: 10.1080/00362178285380381
pubmed: 6760416
Keckich DW, Blair JE, Vikram HR et al (2011) Reactivation of coccidioidomycosis despite antifungal prophylaxis in solid organ transplant recipients. Transplantation 92:88–93
doi: 10.1097/TP.0b013e31821c1df6
pubmed: 21516063
Jones JL, Fleming PL, Ciesielski CA et al (1995) Coccidioidomycosis among persons with AIDS in the United States. J Infect Dis 171:961–964. https://doi.org/10.1093/infdis/171.4.961
doi: 10.1093/infdis/171.4.961
pubmed: 7706825
Shubitz LF, Powell DA, Butkiewicz CD et al (2021) A chronic murine disease model of coccidioidomycosis using Coccidioides posadasii, strain 1038. J Infect Dis 223:166–173. https://doi.org/10.1093/infdis/jiaa419
doi: 10.1093/infdis/jiaa419
pubmed: 32658292
Shubitz LF, Robb EJ, Powell DA et al (2021) Δcps1 vaccine protects dogs against experimentally induced coccidioidomycosis. Vaccine 39:6894–6901. https://doi.org/10.1016/j.vaccine.2021.10.029
doi: 10.1016/j.vaccine.2021.10.029
pubmed: 34696935
pmcid: 9186468
Huppert M, Sun SH, Gross AJ (1972) Evaluation of an experimental animal model for testing antifungal substances. Antimicrob Agents Chemother 1:367–372
doi: 10.1128/AAC.1.5.367
pubmed: 4670475
pmcid: 444225
Mead HL, Van Dyke MCC, Barker BM (2020) Proper care and feeding of Coccidioides: A laboratorian's guide to cultivating the dimorphic stages of C. immitis and C. posadasii. Curr Protoc Microbiol 58:e113. https://doi.org/10.1002/cpmc.113
doi: 10.1002/cpmc.113
pubmed: 32894648
pmcid: 9976608
Dodelet-Devillers A, Zullian C, Vachon P et al (2016) Assessment of stability of ketamine-xylazine preparations with or without acepromazine using high performance liquid chromatography-mass spectrometry. Can J Vet Res 80:86–89
pubmed: 26733737
pmcid: 4686039
Vogler AJ, Nottingham R, Parise KL et al (2015) Effective disinfectants for Coccidioides immitis and C. posadasii. Appl Biosafety 20:154–158. https://doi.org/10.1177/153567601502000306
doi: 10.1177/153567601502000306
Kirkland TN, Fierer J (1983) Inbred mouse strains differ in resistance to lethal Coccidioides immitis infection. Infect Immun 40:912–916. https://doi.org/10.1128/IAI.40.3.912-916.1983
doi: 10.1128/IAI.40.3.912-916.1983
pubmed: 6852925
pmcid: 348138
Kamberi P, Sobel RA, Clemons KV et al (2003) A murine model of coccidioidal meningitis. J Infect Dis 187:453–460
doi: 10.1086/367961
pubmed: 12552429
Wiederhold NP, Shubitz LF, Najvar LK et al (2018) The novel fungal Cyp51 inhibitor VT-1598 is efficacious in experimental models of central nervous system coccidioidomycosis caused by Coccidioides posadasii and Coccidioides immitis. Antimicrob Agents Chemother 62:e02258
doi: 10.1128/AAC.02258-17
pubmed: 29437615
pmcid: 5913997
Shubitz LF, Trinh HT, Galgiani JN et al (2015) Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models. Antimicrob Agents Chemother 59:7249–7254. https://doi.org/10.1128/AAC.00593-15
doi: 10.1128/AAC.00593-15
pubmed: 26369964
pmcid: 4649211
Huppert M, Sun SH, Gleason-Jordan I et al (1976) Lung weight parallels disease severity in experimental coccidioidomycosis. Infect Immun 14:1356–1368
doi: 10.1128/iai.14.6.1356-1368.1976
pubmed: 1002301
pmcid: 415539